Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Technical analysis for shorts & longs -- Ignore unavailable to you. Want to Upgrade?

To: Johnny Canuck who wrote (32593)	6/4/2001 10:28:55 AM
From: Johnny Canuck	Read Replies (1) \| Respond to of 70681

08:13 ET Yahoo! (YHOO) 19.46: SG Cowen upgrades YHOO to a NEUTRAL from a Sell; says Internet advertising channel checks reveal that budgets have stabilized and believes YHOO will make its Q2 results and will indicate better H2 visibility. Q3 will still be seasonally weak, but Fortune 500 ad dollars are starting to flow. 08:08 ET Cypress Semi (CY) 21.60: CY warns that Q2 revenues will be in the $175-185 mln range with EPS of breakeven to $0.02 vs current First Call estimates of $202 mln and $0.03; company says that business conditions have not materially improved in the market segments that it serves. 07:41 ET Cisco Systems (CSCO) 18.85: -- Update -- Britain's Sunday Business reporting that Cisco is considering a bid for Marconi (MONI), but Briefing.com sees little about this deal makes sense. There is too much overlap in products between the two companies, and Cisco buys technology not market share. Also, Cisco has indicated that it would not make any acquisitions at the same time that it is laying off employees. Perhaps the layoffs have ebbed, but making its largest purchase ever just after the recent layoffs would seem highly unlikely. 07:27 ET DuPont (DD) 46.07: According to the WSJ a number of companies are looking to bolster their drug pipeline through the acquisition of the DD drug business including: Bristol Myers, Novartis and Bayer, with the selling price now expected to exceed $6 bln. 07:26 ET Oracle Corp (ORCL) 15.86 +0.56: Robertson Stephens remains cautious on ORCL; firm thinks that the May qtr-aside from the $0.03-$0.06 EPS miss expected by the Street-will be light on the top line; believes stock is fairly valued at current levels given the high degree of uncertainty about the business and risk to ests. Does note however that on Fri, ORCL announced plans to report Q4:F01 results on June 18 th -suggesting that the co will not pre-release earnings or provide commentary on the qtr for another two weeks. Although it is possible that ORCL does in fact pre-announce, this was a positive surprise.